EBV-stimulated cytotoxic T-lymphocyte immunotherapy (Dana-Farber Cancer Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEBV-stimulated cytotoxic T-lymphocyte immunotherapy (Dana-Farber Cancer Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsNot applicable

Therapy Area/IndicationsNasopharyngeal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesDana-Farber Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute

Inactive CompaniesN/A

Active IndicationsNasopharyngeal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A